Page 154 - Syndipharma
P. 154
Contact details: IRANIAN PHARMACEUTICAL COMPANIES DIRECTORY
Head Office:
No. 13, Mirza Hassani, Qaem Maqam Farahani St., Tehran, 1586767114, IRAN
Tel: +98-21-83879000 (Ext.: 134 & 135, 138) Fax: +98-21-88713824
E-mail: export1@sobhanoncology.com
Website: www.sobhanoncology.com
Product List:
Dosage
Type Product Strength Indication (FDA approved) Status
form
Supple- Avemar 17 g Sachet Supplement In Market
ment
Bicalutamide 50 mg
Drug Tab. Prostate Cancer In Market
(Bicalumid®) 150 mg
Drug Bortezomib Vial 3.5 mg Multiple myeloma, Lymphoma In Market
Drug Capecitabine Tab. 500 mg Breast Cancer, Colorectal Cancer In Market
(Oncocap®)
Carboplatin 50 mg/ 5 ml
Drug Vial Ovarian Cancer In Market
(Carboplat®) 150 mg/ 15 ml
Cisplatin 50 mg/ 50 ml Bladder Cancer, Testicular Cancer,
Drug Vial In Market
(Cisplat®) 10 mg/ 20 ml Ovarian Cancer
Drug Doxorubicin Vial 20 mg/ 10 ml Ovarian Cancer, Multiple Myeloma, Contract Manufac-
turing
Kaposi’s Sarcoma
Liposomal
Erlotinib 100 mg Lung Cancer (NSCLC),
Drug Tab. In Market
(Tarsoban®) 150 mg Pancreatic Cancer
Drug Flutamide Tab. 250 mg Prostate Cancer In Market
(Sotamide®)
153
you can find the rest of the product list on page 358
